Healing efficacy in lung adenocarcinoma after targeted therapy, Covid 19 disease and radiosurgery of brain metastasеs

{"title":"Healing efficacy in lung adenocarcinoma after targeted therapy, Covid 19 disease and radiosurgery of brain metastasеs","authors":"","doi":"10.33140/mcr.06.030","DOIUrl":null,"url":null,"abstract":"Lung adenocarcinoma is a common disease, in which high mortality is due to both men and women. In the article we present a 58-year-old man who has been diagnosed with metastatic pulmonary adenocarcinoma/T2B N2 M1a in 2018, on the occasion of dry irritating cough and shortness of breath. Also a positive EGFR mutations has been proven. Targeted therapy (TT) with gefitinib has been carried out for two years till 2020. The patient has been switched on osimertinib in 2020 due to local progression. Brain metastasis has been found in 2021. Radiosurgery (RS) with a singal fraction 15Gy was conducted for treatment of 4 brain metastases . The patient was infected after RS with Covid 19 in April 2021. Patients with specific EGFR mutations can be effectively treated with TT. After treatment with TT, brain metastases of pulmonary adenocarcinoma with specific EGFR mutations are more radiоsensibility and responded very well by high single radiation dose realized by radiosurgery (RS). Despite the worsened prognosis, including Covid 19 disease, by combining TT and RS, we achieved three-year survival in metastatic lung adenocarcinoma.","PeriodicalId":9304,"journal":{"name":"British Medical Journal (Clinical research ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Medical Journal (Clinical research ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/mcr.06.030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Lung adenocarcinoma is a common disease, in which high mortality is due to both men and women. In the article we present a 58-year-old man who has been diagnosed with metastatic pulmonary adenocarcinoma/T2B N2 M1a in 2018, on the occasion of dry irritating cough and shortness of breath. Also a positive EGFR mutations has been proven. Targeted therapy (TT) with gefitinib has been carried out for two years till 2020. The patient has been switched on osimertinib in 2020 due to local progression. Brain metastasis has been found in 2021. Radiosurgery (RS) with a singal fraction 15Gy was conducted for treatment of 4 brain metastases . The patient was infected after RS with Covid 19 in April 2021. Patients with specific EGFR mutations can be effectively treated with TT. After treatment with TT, brain metastases of pulmonary adenocarcinoma with specific EGFR mutations are more radiоsensibility and responded very well by high single radiation dose realized by radiosurgery (RS). Despite the worsened prognosis, including Covid 19 disease, by combining TT and RS, we achieved three-year survival in metastatic lung adenocarcinoma.
肺腺癌靶向治疗、新冠肺炎和脑转移灶放疗后的疗效观察
肺腺癌是一种常见病,男女死亡率都很高。在本文中,我们报告了一名58岁的男性,他于2018年被诊断为转移性肺腺癌/T2B N2 M1a,出现干性刺激性咳嗽和呼吸短促。EGFR阳性突变也已被证实。吉非替尼靶向治疗(TT)已经进行了两年,直到2020年。由于局部进展,该患者已于2020年开始使用奥西替尼。2021年发现了脑转移。采用信号分数15Gy的放射手术治疗4例脑转移瘤。该患者于2021年4月在RS后感染了Covid - 19。具有特异性EGFR突变的患者可以用TT有效治疗。经TT治疗后,特异EGFR突变的肺腺癌脑转移灶具有较高的放射敏感性,放射外科(RS)实现的高单次放射剂量反应良好。尽管预后恶化,包括Covid - 19疾病,但通过联合TT和RS,我们实现了转移性肺腺癌的三年生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信